Welcome to our dedicated page for CorMedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CorMedix's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CorMedix's regulatory disclosures and financial reporting.
CorMedix Inc. filed a Form 144 reporting a proposed sale of 53,997 common shares through Merrill Lynch on 09/09/2025. The filing lists an aggregate market value of $728,959.00 and indicates 74,648,992 shares outstanding for the issuer. The shares were acquired the same day (09/09/2025) under a stock plan activity from the issuer, with payment recorded as n/a. No securities were reported sold by the filer in the prior three months. The notice includes the standard statement that the seller does not possess undisclosed material adverse information and warns that false statements are criminally punishable.
CorMedix insider amendment reports a tax-withholding share disposition by Elizabeth Hurlburt, the company's Chief Operating Officer and a director. The filing shows 8,424 shares of common stock were withheld by the issuer at an effective price of $14.83 to satisfy the reporting person's tax liability, reducing her direct beneficial ownership to 176,990 shares. The Form 4/A amends an earlier filing to disclose this withheld amount. The disclosure is a mechanical equity withholding for taxes rather than an open-market sale and does not report derivative transactions.
Beth Zelnick Kaufman, Chief Legal Officer and Director of CorMedix Inc. (CRMD), reported a non-derivative disposition of 8,880 shares of common stock executed on 08/29/2025 at a price of $14.83 per share. The transaction reflects the issuer withholding 8,880 shares to satisfy the reporting person's tax withholding obligation, which was omitted from an earlier filing and is corrected here. After the withheld shares, the reporting person beneficially owns 180,418 shares. The amendment clarifies the nature of the disposition and updates the ownership total.
Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (CRMD), was granted 69,686 restricted stock units on 08/29/2025. Each unit represents one share and the grant price is listed as $0. The RSUs vested one-quarter on the grant date and vest in three additional equal annual installments, subject to continued employment. Following the reported transaction, Ms. Hurlburt beneficially owned 185,414 shares. The Form 4 was signed by Ms. Hurlburt on 09/03/2025.
CorMedix Inc. (CRMD) Chief Legal Officer Beth Zelnick Kaufman received a grant of 69,686 restricted stock units on 08/29/2025, reported on Form 4. Each unit converts to one share and was granted at no cash price ($0). Following the grant, Ms. Zelnick Kaufman beneficially owned 189,298 shares. The restricted stock units vested 1/4 immediately on the grant date and the remainder in three equal annual installments on each anniversary, subject to continued employment. The Form 4 was signed and dated 09/03/2025.
Susan Blum, Chief Financial Officer of CorMedix Inc. (CRMD), was granted 69,686 restricted stock units (RSUs) on 08/29/2025. Each RSU converts to one share of common stock and the award was recorded at a $0 price, indicating a service-based grant rather than a purchase. The RSUs vest in four equal installments on the first four anniversaries of the grant date, contingent on continued employment. Following the grant, Ms. Blum beneficially owns 69,686 shares directly as reported on the Form 4. The filing is signed by Ms. Blum on 09/03/2025 and lists her role as Chief Financial Officer.
CorMedix Inc. Chief Financial Officer Susan Blum filed an initial ownership report on Form 3 in connection with her role as an officer of CorMedix Inc. The filing states that no securities of CorMedix Inc. are beneficially owned, and both the non-derivative and derivative ownership tables show no holdings. The form is filed by a single reporting person in her capacity as Chief Financial Officer.
CorMedix Inc. (CRMD) has filed a Form 144 reporting a proposed sale of 300,000 common shares through Merrill Lynch on 09/03/2025 on the NASDAQ, with an aggregate market value of $4,350,000.00. The filing shows the shares were acquired and are to be paid for on 09/03/2025 under a Stock Plan Activity from the issuer. The company reports 74,648,992 shares outstanding, so the proposed sale represents approximately 0.40% of outstanding common stock. The filer indicates there were no shares sold by the same person in the past three months and includes the standard certification that no material nonpublic information is known by the seller.
CorMedix Inc. filed an 8-K that includes a press release dated September 2, 2025 and is signed by CEO Joseph Todisco. The filing discloses contingent payment obligations tied to potential FDA-approved labeling: $20 million if labeling includes candida, $2.5 million if labeling includes aspergillus, and $2.5 million if labeling includes pneumocystis. Portions of an exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K. The document also contains contact information and standard exchange-act checkbox items, but the text provided here appears truncated and does not include the full press release or additional financial detail.
CorMedix Inc. completed its previously announced private placement of $150,000,000 aggregate principal amount of convertible senior notes due 2030, issued in reliance on Section 4(a)(2) of the Securities Act. The company entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, and the indenture and form of note are filed as Exhibits 4.1 and 4.2.
The notes bear a stated rate reflected in the form of the notes as 4.00% and have an initial conversion rate of 74.2515 shares per $1,000 principal amount (approximately $13.47 per share implied by that rate). The notes and any common stock issuable upon conversion have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.